Bladder cancer updates from the second half of 2026
Bladder cancer updates from the second half of 2026
ESMO 2026: Prostate cancer roundup
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety
Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer
Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer
Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC
ESMO 2026: Highlights and analysis
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer
Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer
WCLC 2026: Lung cancer research highlights
Quality improvement initiative reduces chemotherapy wastage in paediatric oncology in Pakistan